These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 37231941)
1. A retrospective analysis of secondary cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in patients with recurrent ovarian cancer. Yang D; Zhang Y; Gong P; Liu F; Gan Y; Bai W J Obstet Gynaecol Res; 2023 Jul; 49(7):1795-1804. PubMed ID: 37231941 [TBL] [Abstract][Full Text] [Related]
2. Secondary cytoreductive surgery followed by olaparib tablets as maintenance therapy in patients with BRCA mutated recurrent ovarian cancer: A multi-center retrospective study. Yang D; Zhang Y; Gong P; Ren S; Gan Y; Liu F; Wang C; Zhao X; Liu R; Bai W Eur J Surg Oncol; 2024 Feb; 50(2):107950. PubMed ID: 38215549 [TBL] [Abstract][Full Text] [Related]
3. Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial. Lim MC; Chang SJ; Park B; Yoo HJ; Yoo CW; Nam BH; Park SY; JAMA Surg; 2022 May; 157(5):374-383. PubMed ID: 35262624 [TBL] [Abstract][Full Text] [Related]
4. Effect of platinum sensitivity on the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in recurrent epithelial ovarian cancer. Costales AB; Chambers L; Chichura A; Rose PG; Mahdi H; Michener CM; Yao M; Debernardo R J Gynecol Obstet Hum Reprod; 2021 May; 50(5):101844. PubMed ID: 32590110 [TBL] [Abstract][Full Text] [Related]
5. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. van Driel WJ; Koole SN; Sikorska K; Schagen van Leeuwen JH; Schreuder HWR; Hermans RHM; de Hingh IHJT; van der Velden J; Arts HJ; Massuger LFAG; Aalbers AGJ; Verwaal VJ; Kieffer JM; Van de Vijver KK; van Tinteren H; Aaronson NK; Sonke GS N Engl J Med; 2018 Jan; 378(3):230-240. PubMed ID: 29342393 [TBL] [Abstract][Full Text] [Related]
6. Hyperthermic Intraperitoneal Chemotherapy After Interval Cytoreductive Surgery for Patients With Advanced-Stage Ovarian Cancer Who Had Received Neoadjuvant Chemotherapy. Lee JY; Lee YJ; Son JH; Kim S; Choi MC; Suh DH; Song JY; Hong DG; Kim MK; Kim JH; Chang SJ JAMA Surg; 2023 Nov; 158(11):1133-1140. PubMed ID: 37672264 [TBL] [Abstract][Full Text] [Related]
7. Prognostic value and adverse events of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in primary advanced and platinum-sensitive recurrent epithelial ovarian cancer: a systematic review and meta-analysis. Xia Y; Wang H; Zhang J; Wang Y Int J Hyperthermia; 2023; 40(1):2165729. PubMed ID: 36775583 [TBL] [Abstract][Full Text] [Related]
8. Hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer. Chen WC; Huang HJ; Yang LY; Pan YB; Huang KG; Lin CT; Chen MY; Tang YH; Chang TC; Lai CH; Chou HH Biomed J; 2022 Oct; 45(5):821-827. PubMed ID: 34656802 [TBL] [Abstract][Full Text] [Related]
9. Patterns of recurrence in women with advanced and recurrent epithelial ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Chambers LM; Yao M; Morton M; Gruner M; Chichura A; Horowitz M; Costales AB; Rose PG; Michener CM; Debernardo R Gynecol Oncol; 2021 May; 161(2):389-395. PubMed ID: 33551202 [TBL] [Abstract][Full Text] [Related]
10. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial. Aronson SL; Lopez-Yurda M; Koole SN; Schagen van Leeuwen JH; Schreuder HWR; Hermans RHM; de Hingh IHJT; van Gent MDJM; Arts HJG; van Ham MAPC; van Dam PA; Vuylsteke P; Aalbers AGJ; Verwaal VJ; Van de Vijver KK; Aaronson NK; Sonke GS; van Driel WJ Lancet Oncol; 2023 Oct; 24(10):1109-1118. PubMed ID: 37708912 [TBL] [Abstract][Full Text] [Related]
11. Hyperthermic intraperitoneal chemotherapy in the treatment of recurrent ovarian cancer: When, and for whom? Ayhan A; Akilli H; Abasiyanik MA; Taskiran C J Surg Oncol; 2023 Mar; 127(3):457-464. PubMed ID: 36264620 [TBL] [Abstract][Full Text] [Related]
12. Ten-year treatment outcomes of consolidation hyperthermic intraperitoneal chemotherapy for ovarian cancer (HIPEC-KOV-03R). Yoo JG; Kim JH; Park EY; Kim I; Lim MC; Lee SJ J Gynecol Oncol; 2023 Nov; 34(6):e72. PubMed ID: 37417300 [TBL] [Abstract][Full Text] [Related]
13. Role of Hyperthermic Intraperitoneal Chemotherapy Combined with Cytoreductive Surgery as Consolidation Therapy for Advanced Epithelial Ovarian Cancer. Frankinet L; Bhatt A; Alcazer V; Classe JM; Bereder JM; Meeus P; Pomel C; Mithieux F; Abboud K; Wermert R; Lavoue V; Marchal F; Glehen O; Bakrin N Ann Surg Oncol; 2023 Jun; 30(6):3287-3299. PubMed ID: 36820940 [TBL] [Abstract][Full Text] [Related]
14. Laparoscopic versus open approach for interval cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in advanced epithelial ovarian cancer: a matched comparative study. Durán-Martínez M; Gómez-Dueñas G; Rodriguez-Ortíz L; Sanchez-Hidalgo JM; Gordón-Suárez A; Casado-Adam Á; Rufián-Peña S; Valenzuela-Molina F; Rufián-Andujar B; Vázquez-Borrego MC; Romero-Ruiz A; Briceño-Delgado J; Arjona-Sánchez Á Surg Endosc; 2024 Jan; 38(1):66-74. PubMed ID: 37903884 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Stage III Epithelial Ovarian Cancer. Lei Z; Wang Y; Wang J; Wang K; Tian J; Zhao Y; Chen L; Wang J; Luo J; Jia M; Tang H; He Q; Liao Q; Yang X; Guan T; Wang L; Cui S; JAMA Netw Open; 2020 Aug; 3(8):e2013940. PubMed ID: 32840622 [TBL] [Abstract][Full Text] [Related]
16. Cytoreduction (Peritonectomy Procedures) Combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Advanced Ovarian Cancer: Retrospective Italian Multicenter Observational Study of 511 Cases. Di Giorgio A; De Iaco P; De Simone M; Garofalo A; Scambia G; Pinna AD; Verdecchia GM; Ansaloni L; Macrì A; Cappellini P; Ceriani V; Giorda G; Biacchi D; Vaira M; Valle M; Sammartino P Ann Surg Oncol; 2017 Apr; 24(4):914-922. PubMed ID: 27896512 [TBL] [Abstract][Full Text] [Related]
17. Cytoreductive Surgery (CRS) Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Platinum-Sensitive Recurrence Epithelial Ovarian Cancer With HRR Mutation: A Phase III Randomized Clinical Trial. Qi Y; Zhang Y; Shi Y; Yao S; Dai M; Cai H Technol Cancer Res Treat; 2022; 21():15330338221104565. PubMed ID: 35929135 [No Abstract] [Full Text] [Related]
18. Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with primary or secondary cytoreductive surgery in the treatment of advanced epithelial ovarian cancer. Manzanedo I; Pereira F; Pérez-Viejo E; Serrano Á; Hernández-García M; Martínez-Torres B; Rihuete-Caro C; Calzas J; Cueto M Minerva Ginecol; 2017 Apr; 69(2):119-127. PubMed ID: 27415829 [TBL] [Abstract][Full Text] [Related]
19. Outcomes for Elderly Ovarian Cancer Patients Treated with Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC). Zambrano-Vera K; Sardi A; Lopez-Ramirez F; Sittig M; Munoz-Zuluaga C; Nieroda C; Gushchin V; Diaz-Montes T Ann Surg Oncol; 2021 Aug; 28(8):4655-4666. PubMed ID: 33393042 [TBL] [Abstract][Full Text] [Related]
20. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of advanced epithelial ovarian carcinoma: upfront therapy, at first recurrence, or later? Gonzalez Bayon L; Steiner MA; Vasquez Jimenez W; Asencio JM; Alvarez de Sierra P; Atahualpa Arenas F; Rodriguez del Campo J; Garcia Sabrido JL Eur J Surg Oncol; 2013 Oct; 39(10):1109-15. PubMed ID: 23870278 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]